Format

Send to

Choose Destination
Psychooncology. 2015 Dec;24(12):1731-7. doi: 10.1002/pon.3840. Epub 2015 May 8.

Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life.

Author information

1
Massachusetts General Hospital Cancer Center, Boston, MA, USA.
2
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Abstract

INTRODUCTION:

Administration of chemotherapy in the last 14 days of life is a widely recognized indicator of poor end-of-life (EOL) care. The current study aimed to investigate predictors of this outcome, focusing on patients' self-reported psychological symptoms.

METHODS AND MATERIALS:

This is a secondary analysis of a randomized controlled trial that examined the efficacy of early palliative care integrated with standard oncology practice in patients with metastatic non-small cell lung cancer (NSCLC). We analyzed associations between receipt of chemotherapy within 14 days of death and demographic, clinical, and quality-of-life variables in the 125 patients who received chemotherapy in the course of their illness and died during the 50-month follow-up.

RESULTS:

Twenty-five patients (20%) received chemotherapy within the last 14 days of their life. Among demographic and clinical variables, only route of chemotherapy was significantly associated with receipt of chemotherapy within 14 days of death (oral 34.1% vs. intravenous (i.v.) 12.3%, p < 0.05). In the subsample of participants who received i.v. chemotherapy as their last regimen, greater anxiety and depression and lower quality of life in emotional, social, and existential domains were associated with greater likelihood of receiving chemotherapy at the EOL. These associations were not observed in patients who received oral chemotherapy as their last regimen.

CONCLUSION:

Anxiety, depression, and worse psychological quality of life at early stage of treatment may be associated with the receipt of i.v. chemotherapy at the EOL. Further research is needed to examine how these factors might influence decision-making about the discontinuation of chemotherapy at the EOL.

PMID:
25959002
DOI:
10.1002/pon.3840
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center